SearchDictionaryMobileLogin

Colin L Masters Selected Research

Alzheimer Disease (Alzheimer's Disease)

10/2008The structure of the amyloid-beta peptide high-affinity copper II binding site in Alzheimer disease.
05/2008Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease.
05/2008Crystallization and preliminary X-ray diffraction analysis of the Fab fragment of WO2, an antibody specific for the Abeta peptides associated with Alzheimer's disease.
04/2008Stabilization of neurotoxic soluble beta-sheet-rich conformations of the Alzheimer's disease amyloid-beta peptide.
02/2008Selective Intracellular Release of Copper and Zinc Ions from Bis(thiosemicarbazonato) Complexes Reduces Levels of Alzheimer Disease Amyloid-{beta} Peptide.
02/2008Imaging of amyloid beta in Alzheimer's disease with (18)F-BAY94-9172, a novel PET tracer: proof of mechanism.
11/2007Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.
11/2007Differential modulation of Alzheimer's disease amyloid beta-peptide accumulation by diverse classes of metal ligands.
04/2007Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease.
03/2007Concentration dependent Cu2+ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-beta peptide.
06/2006Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity.
06/2006Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics.
04/2006Decreased phosphatidylethanolamine binding protein expression correlates with Abeta accumulation in the Tg2576 mouse model of Alzheimer's disease.
02/2006Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease.
01/2006Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies.
01/2006Pathways to the discovery of the Abeta amyloid of Alzheimer's disease.
01/2006The beta-amyloid peptide of Alzheimer's disease decreases adhesion of vascular smooth muscle cells to the basement membrane.
06/2005Metals and amyloid-beta in Alzheimer's disease.
04/2005The amyloid precursor protein (APP) of Alzheimer disease and its paralog, APLP2, modulate the Cu/Zn-Nitric Oxide-catalyzed degradation of glypican-1 heparan sulfate in vivo.
04/2005Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity.
01/2005Crystallization and preliminary crystallographic studies of the copper-binding domain of the amyloid precursor protein of Alzheimer's disease.
09/2004Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid.
08/2004Expression of truncated presenilin 2 splice variant in Alzheimer's disease, bipolar disorder, and schizophrenia brain cortex.
06/2004Increased beta-Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects.
04/2004Characterizing bathocuproine self-association and subsequent binding to Alzheimer's disease amyloid beta-peptide by NMR.
12/2003Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.
11/2003Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
11/2003Proteasome-mediated degradation of the C-terminus of the Alzheimer's disease beta-amyloid protein precursor: effect of C-terminal truncation on production of beta-amyloid protein.
09/2003Copper, beta-amyloid, and Alzheimer's disease: tapping a sensitive connection.
09/2003Two novel presenilin-1 mutations (Y256S and Q222H) are associated with early-onset Alzheimer's disease.
05/2003Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis.
04/2003Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease.
02/2003Selecting cells with different Alzheimer's disease gamma-secretase activity using FACS. Differential effect on presenilin exon 9 gamma- and epsilon-cleavage.
01/2003Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-beta peptide with membrane lipid.
12/2002Mechanisms of peripheral microvascular dysfunction in transgenic mice overexpressing the Alzheimer's disease amyloid Abeta protein.
11/2002Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron.
10/2002Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2).
06/2002Alzheimer's disease amyloid beta and prion protein amyloidogenic peptides promote macrophage survival, DNA synthesis and enhanced proliferative response to CSF-1 (M-CSF).
06/2002Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease.
01/2002Contrasting, species-dependent modulation of copper-mediated neurotoxicity by the Alzheimer's disease amyloid precursor protein.

Articles by Research Topic

Disease

40Alzheimer Disease (Alzheimer's Disease)
10/2008 - 01/2002
4Dementia (Dementias)
04/2008 - 04/2002
3Prion Diseases (Transmissible Spongiform Encephalopathies)
07/2008 - 12/2005
3Creutzfeldt-Jakob Syndrome (Creutzfeldt-Jakob Disease)
01/2008 - 10/2002
3Parkinson Disease (Parkinson's Disease)
04/2007 - 08/2002
1Syndrome
08/2007
1Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
04/2006
1Tissue Adhesions
01/2006
1Bipolar Disorder (Mania)
08/2004
1Schizophrenia (Dementia Praecox)
08/2004
1Encephalomyelitis (Myeloencephalitis)
08/2003
1Cataract (Cataracts)
04/2003

Drug/Important Bio-Agent (IBA)

31Amyloid (Amyloid Fibrils)IBA
10/2008 - 01/2002
7CopperIBA
10/2008 - 01/2002
4Amyloid Precursor Protein Secretases (beta-Secretase)IBA
01/2006 - 06/2002
3Presenilin-1IBA
09/2003 - 04/2002
2Superoxide DismutaseIBA
07/2008 - 04/2005
2PeptidesIBA
05/2008 - 06/2002
2IonsIBA
02/2008 - 01/2003
2Clioquinol (Vioform)FDA Link
02/2006 - 12/2003
1CatalaseIBA
07/2008
1PlatinumIBA
05/2008
1ZincIBA
02/2008
1PrionsIBA
01/2008
1LigandsIBA
11/2007
1CarbonIBA
08/2007
12- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA
08/2007
1alpha-SynucleinIBA
04/2007
1N- methyl- 2- (4'- methylaminophenyl)- 6- hydroxybenzothiazoleIBA
04/2007
1Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
04/2007
1dityrosineIBA
03/2007
1Protein-Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA
11/2006
1superoxide dismutase 1IBA
04/2006
1Phosphatidylethanolamine Binding ProteinIBA
04/2006
1PrPSc ProteinsIBA
01/2006
1Monoclonal AntibodiesIBA
12/2005
1EpitopesIBA
12/2005
1Nitric Oxide (Nitrogen Monoxide)FDA Link
04/2005
1imidazoleIBA
04/2005
1Heparitin Sulfate (Heparan Sulfate)IBA
04/2005
1GlypicansIBA
04/2005
1Tyrosine (L-Tyrosine)FDA Link
09/2004
1Presenilin-2IBA
08/2004
1bathocuproineIBA
04/2004
1LyoduraIBA
02/2004
1Amyloid beta-ProteinIBA
11/2003
1Proteasome Endopeptidase Complex (Proteasome)IBA
11/2003
1Amyloid beta-Protein Precursor (Amyloid Protein Precursor)IBA
11/2003
1Oligoclonal BandsIBA
08/2003
1CholesterolIBA
01/2003
1IronIBA
11/2002
1Quinacrine (Mepacrine)IBA
10/2002
1SynucleinsIBA
08/2002
1DNA (Deoxyribonucleic Acid)IBA
06/2002
1Macrophage Colony-Stimulating FactorIBA
06/2002

Therapy/Procedure

1Therapeutics
06/2006
1Lenses
04/2003